Theravance Biopharma (TBPH) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Sales: YUPELRI achieved net sales of $71.4 million in Q3 2025, a 15% increase year-over-year, driven by strong demand and favorable pricing.

Profitability: Record brand profitability was noted, leading to non-GAAP breakeven for the quarter.

Cash Position: Theravance ended Q3 with approximately $333 million in cash and no debt.

Milestones: The company is on track to achieve $75 million in milestones in Q4, including $50 million from Trelegy and $25 million from YUPELRI.

2Strategic Updates and Business Highlights

YUPELRI Performance: Continued strong performance in both hospital and outpatient channels, with hospital volume increasing by 29% year-over-year. The brand's market share in the long-acting nebulized hospital market reached 21%.

Ampreloxetine Development: The pivotal Phase III Cyprus trial is progressing, with top-line results expected in early 2026. The company hosted a KOL event to discuss the unmet medical need for neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

Educational Campaign: A new disease education campaign was launched to raise awareness about nOH associated with MSA.

3Forward Guidance and Outlook

Q4 Expectations: The company expects to maintain consistent results in Q4, with anticipated milestone payments contributing to cash inflow in 2026.

Long-term Potential: The upcoming Cyprus data readout is viewed as a significant potential value inflection point for the company, with expectations for ampreloxetine to become a first-line therapy for nOH in MSA.

4Bad News, Challenges, or Points of Concern

Market Competition: There are ongoing competitive pressures in the respiratory market, particularly for YUPELRI, which may impact future growth.

Execution Risks: The success of the Cyprus trial is critical; any unfavorable results could significantly affect the company’s strategic direction and financial outlook.

Capital Allocation: While there is a commitment to returning capital to shareholders, the need to maintain sufficient cash reserves for the ampreloxetine launch poses a balancing challenge.

5Notable Q&A Insights

Capital Return Strategy: CEO Rick Winningham emphasized that while there is a focus on returning capital to shareholders, the priority remains on executing the Cyprus study and preparing for the ampreloxetine launch.

Clinical Expectations: Questions regarding the minimally clinically important difference (MCID) for the Cyprus data were addressed, with management expressing confidence in achieving clinically meaningful results based on previous studies.

Enrollment in Cyprus Study: Aine Miller confirmed that while specific enrollment numbers were not disclosed, the study is adequately powered to detect treatment differences, with operational execution progressing well. Overall, Theravance Biopharma reported a strong quarter with solid financial performance and strategic advancements, while also highlighting the critical nature of upcoming clinical data and market dynamics.